Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:13:40 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:TYRA - TYRA BIOSCIENCES INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TYRA - Q0.19.09·10.950.210.39-0.47-4.3104.21,0162,00611.00  11.1925  10.3829.60  6.4216:43:28Jul 0815 min RT 2¢

Recent Trades - Last 10 of 2006
Time ETExPriceChangeVolume
16:43:28Q10.81-0.05200
16:04:14Q10.39-0.471
16:04:02Q10.39-0.471
16:02:04Q10.39-0.47137
16:02:00Q10.39-0.47212
16:00:21Q10.39-0.47200
16:00:21Q10.39-0.47145
16:00:21Q10.39-0.4739
16:00:21Q10.39-0.47793
16:00:21Q10.39-0.473

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-08 16:05U:TYRANews ReleaseTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
2025-06-30 08:00U:TYRANews ReleaseTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
2025-05-12 16:05U:TYRANews ReleaseTyra Biosciences to Participate at Upcoming Investor Conferences
2025-05-08 16:05U:TYRANews ReleaseTyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
2025-03-27 16:05U:TYRANews ReleaseTyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
2025-02-11 16:05U:TYRANews ReleaseTyra Biosciences to Present at Upcoming Investor Conferences
2025-01-29 16:05U:TYRANews ReleaseTyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
2025-01-22 08:00U:TYRANews ReleaseTyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
2025-01-10 08:00U:TYRANews ReleaseTyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
2024-11-13 16:05U:TYRANews ReleaseTyra Biosciences to Present at Upcoming Investor Conferences
2024-11-07 16:05U:TYRANews ReleaseTyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
2024-10-28 07:00U:TYRANews ReleaseTyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
2024-10-24 18:05U:TYRANews ReleaseTyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
2024-10-23 16:05U:TYRANews ReleaseTyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
2024-10-11 08:00U:TYRANews ReleaseTyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
2024-09-11 16:05U:TYRANews ReleaseTyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
2024-09-10 16:05U:TYRANews ReleaseTyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
2024-08-07 16:05U:TYRANews ReleaseTyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights